A recent report published by Infinium Global Research on the  immunosuppressant drugs market provides an in-depth analysis of segments and sub-segments in the global as well as regional immunosuppressant drugs market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional immunosuppressant drugs market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global immunosuppressant drugs market. According to the report, the global immunosuppressant drugs market is projected to grow at a CAGR of 4.9% over the forecast period of 2019-2025.

Market Insight

Immunosuppressant drugs are used in post organ transplants. It has applications in the treatment of different autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and psoriasis. After an organ transplant, the immunity of patients has to be subdued to allow the patient’s body to accept the newly planted organ. These are anti-rejection drugs that make the body less likely to reject a transplanted organ such as the heart, liver, or kidney.

The rise in the number of organ transplantation procedures drives the growth of the immunosuppressant drugs market. As per the Global Observatory on Donation and Transplantation report, there was 139024 organ transplantation occurred in 2017. There is a significant increase in organ transplantation procedures in recent years. The rising number of organ transplantation for kidneys, lungs, liver, pancreas, and other organs led to increasing demand for immunosuppressant drugs. Kidney is the most transplanted organ globally. In 2017, 36% of the total number of transplantations was for the kidney. Immunosuppressant drugs play a vital role in the success of organ transplant procedures. Further, the growing prevalence of autoimmune disease owing to changing lifestyles stimulates the expansion of the market. The changes in dietary habits lead to stress, insufficient sleep, unhealthy eating habits, smoking, and different environmental factors that promote the rise in autoimmune diseases such as lupus, celiac disease, and others. The increasing advancements in tissue engineering and organ transplant techniques promote the growth of the immunosuppressant drugs market. Additionally, increasing prevalence of chronic ailments and a rise in demand for organ replacement boost the expansion of the immunosuppressant drugs market. On the flip side, the high cost of the drugs restraints the growth of the immunosuppressant drugs market. Moreover, the adoption of advanced medical treatments and the rising use of tissue engineering create several opportunities for the growth of the immunosuppressant drugs market.

Geographically, the global immunosuppressant drugs market is divided into North America, Asia-Pacific, Europe, and the Rest of the World. North America is expected to hold the largest share in the global immunosuppressant drugs market. The growing prevalence of autoimmune diseases and the increasing number of organ transplants in North America drive the growth of the immunosuppressant drugs market in the region. A study estimated that in the United States around 24 million people are having an autoimmune disease. In addition, as of September 2019, the number of organ transplant candidates in the United States is 112947. Europe is expected to grow in the global immunosuppressant drugs market with a healthy CAGR over the forecast period. The rising number of transplants in Europe contributes to the expansion of the immunosuppressant drugs market in Europe. Asia-Pacific region has lucrative growth opportunities in the global immunosuppressant drugs market owing to the well-established healthcare industry and growing medical tourism in the region.

Segment Covered

The report on global immunosuppressant drugs market covers segments such as drug type, route of administration, application, and end-user. On the basis of drug type, the sub-markets include calcineurin inhibitors, center for biotechnology, antiproliferative agents, imdh inhibitors, and other drug types. On the basis of route of administration, the sub-markets include intravenous, oral, and other routes. On the basis of application, the sub-markets include organ transplant, autoimmune disease, kidney transplant, liver transplant, heart transplant, and other applications. On the basis of end-user, the sub-markets include organ transplant centers, hospitals and clinics, and other end-users.

Companies Profiled:

The report provides profiles of the companies in the market such as Genzyme Corp., Astellas Pharma Inc., Accord Healthcare Ltd., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Mylan Laboratories Ltd., Pfizer Inc., Novartis International AG, and Other companies.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the immunosuppressant drugs market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.